Bristol-Myers Squibb is one of the world’s leading pharmaceutical companies.
Bristol-Myers Squibb generated $48.2 billion in total revenues in 2025 — essentially flat year-on-year — as growth portfolio momentum from Opdivo, Breyanzi, Reblozyl, Camzyos, and the newly launched Cobenfy was offset by accelerating declines in the legacy portfolio. BMS’s growth portfolio generating $26.4 billion in 2025 revenues, up 17%, is the most important metric for understanding the company’s trajectory. The company’s strategic restructuring under CEO Chris Boerner targets $1.5 billion in cost savings by end of 2025 with a further $2 billion by end of 2027.
This report provides comprehensive strategic intelligence on Bristol-Myers Squibb — covering strategic directions, financial performance, SWOT analysis, technological know-how, latest products and services, M&A, marketing tactics, and organization and management.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and key platforms
• Latest products, programs, and innovation pipeline
• M&A activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Bristol-Myers Squibb — Key Financial Metrics 2023-2025
Table 2. Bristol-Myers Squibb — Revenue by Therapeutic Area 2023-2025
Table 3. Bristol-Myers Squibb — Revenue by Geography 2023-2025
Table 4. Bristol-Myers Squibb — R&D Investment 2023-2025
Table 5. Bristol-Myers Squibb — SWOT Analysis
Table 6. Bristol-Myers Squibb — Key Technology Platforms
Table 7. Bristol-Myers Squibb — Top Products by Revenue 2025
Table 8. Bristol-Myers Squibb — Late-Stage Pipeline 2025
Table 9. Bristol-Myers Squibb — M&A Activity 2023-2025
Table 10. Bristol-Myers Squibb — Key Management
Table 11. Bristol-Myers Squibb — Strategic Priorities 2025-2030
